Zepeda-Rivera, Martha
Minot, Samuel S. http://orcid.org/0000-0003-1639-3905
Bouzek, Heather
Wu, Hanrui
Blanco-MÃguez, Aitor http://orcid.org/0000-0001-7386-5572
Manghi, Paolo http://orcid.org/0000-0003-0846-6529
Jones, Dakota S.
LaCourse, Kaitlyn D.
Wu, Ying
McMahon, Elsa F.
Park, Soon-Nang
Lim, Yun K.
Kempchinsky, Andrew G.
Willis, Amy D.
Cotton, Sean L.
Yost, Susan C.
Sicinska, Ewa
Kook, Joong-Ki http://orcid.org/0000-0003-2628-2870
Dewhirst, Floyd E. http://orcid.org/0000-0003-4427-7928
Segata, Nicola
Bullman, Susan http://orcid.org/0000-0002-7713-0810
Johnston, Christopher D. http://orcid.org/0000-0002-6765-2383
Article History
Received: 19 February 2023
Accepted: 8 February 2024
First Online: 20 March 2024
Competing interests
: S.B. has consulted for GlaxoSmithKline and BiomX. C.D.J. has consulted for Series Therapeutics and Azitra. S.B. is an inventor on US patent application no. PCT/US2018/042966, submitted by the Broad Institute and Dana-Farber Cancer Institute, which covers the targeting of <i>Fusobacterium</i> for the treatment of CRC. S.B., C.D.J. and M.Z.-R. are inventors on US patent application no. F053-0188USP1/22-158-US-PSP, submitted by the Fred Hutchinson Cancer Center, which covers the modulation of cancer-associated microbes. K.D.L. is employed by NanoString Technologies at present. The remaining authors declare no competing interests.